文献速递临床微生物质量管理与危急值

新型快速表型药敏试验技术助力抗菌药物管理与临床决策

Novel Rapid Phenotypic Susceptibility Testing Techniques That Enhance Antimicrobial Stewardship and Clinical Decision-Making.
PubMed 文献 · Clin Chem · 2026-01-01

综述概述新兴快速表型药敏试验技术,聚焦其临床相关性与操作意义,指出该技术能比传统方法更早提供药敏结果,有助于优化抗生素治疗并改善脓毒症等严重感染结局,但面临性能差异、缺乏标准化方案和成本效益等实施挑战。

要点

  • 快速表型药敏试验可显著缩短获得药敏结果的时间。
  • 该技术有助于优化抗生素治疗并支持抗菌药物管理。
  • 实施面临性能差异、缺乏标准化方案和成本效益挑战。

核心结论

  • 快速表型药敏试验是抗击抗菌药物耐药的重要进展,可通过及时、循证的抗菌治疗改善患者结局。

研究设计与样本

  • 本文为综述,概述新兴快速表型药敏试验技术,聚焦其临床相关性与操作意义。

主要发现

  • 快速表型药敏试验比传统方法显著更早提供可操作的药敏结果。
  • 该加速周转对优化抗生素治疗和改善脓毒症等严重感染结局至关重要。
  • 快速表型药敏试验可减少获得有效治疗的时间并支持抗菌药物管理。
  • 实施面临测试性能差异、缺乏标准化方案和成本效益考量等挑战。

临床怎么用

  • 可利用快速表型药敏试验加速获得药敏结果以优化抗生素治疗。
  • 应将快速表型药敏试验纳入抗菌药物管理以支持临床决策。

局限性

  • 测试性能存在差异。
  • 缺乏标准化方案。
  • 成本效益需考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance (AMR) is a critical global health challenge, underscoring the need for diagnostic innovations that enable timely, and targeted therapy. Rapid phenotypic antimicrobial susceptibility testing (AST) offers a transformative approach by delivering actionable susceptibility results significantly earlier than conventional methods. This accelerated turnaround is vital for optimizing antibiotic therapy and improving outcomes in severe infections, such as sepsis, where delays in effective treatment increase morbidity and mortality. Despite these advantages, implementation faces challenges, including variability in test performance, lack of standardized protocols, and cost-benefit considerations. CONTENT: This review provides an overview of emerging rapid phenotypic AST technologies, focusing on their clinical relevance and operational implications. We outline the fundamentals of the phenotypic approach, highlight growth-based methods, and summarize evidence, demonstrating the impact of rapid phenotypic AST on reducing time to effective therapy and supporting antimicrobial stewardship. SUMMARY: Rapid phenotypic AST represents a pivotal advancement in combating AMR, offering the potential to bridge diagnostic gaps and enhance patient outcomes through timely, evidence-based antimicrobial therapy.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Glover JS, Humphries R. Novel Rapid Phenotypic Susceptibility Testing Techniques That Enhance Antimicrobial Stewardship and Clinical Decision-Making. Clin Chem. 2026. PMID: 42028796. doi:10.1093/clinchem/hvag033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。